Lv1
60 积分 2021-06-28 加入
Valemetostat for patients with relapsed or refractory peripheral T-cell lymphoma (VALENTINE-PTCL01): a multicentre, open-label, single-arm, phase 2 study
1天前
已完结
Valemetostat for patients with relapsed or refractory peripheral T-cell lymphoma (VALENTINE-PTCL01): a multicentre, open-label, single-arm, phase 2 study
1天前
已完结
Development of ICT01, a first-in-class, anti-BTN3A antibody for activating Vγ9Vδ2 T cell–mediated antitumor immune response
13天前
已完结
Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B/ACT-2 trial
1个月前
已完结
Update on T-Cell Lymphoma Epidemiology
1个月前
已完结
International Peripheral T-Cell and Natural Killer/T-Cell Lymphoma Study: Pathology Findings and Clinical Outcomes
1个月前
已关闭
Incidence trends for common subtypes of T-cell lymphoma in Taiwan and the United States from 2008–2020
1个月前
已完结
Update on T-Cell Lymphoma Epidemiology
1个月前
已完结
CAR T Cells and T-Cell Therapies for Cancer
2个月前
已完结
Honing CAR T cells to tackle acute myeloid leukemia
2个月前
已关闭
皖公网安备34019202002308
